医学
衰老
疾病
癌症研究
糖尿病肾病
肾脏疾病
细胞
肾
糖尿病
肾干细胞
细胞周期进展
补体系统
药理学
补语(音乐)
药品
细胞衰老
细胞生长
内科学
免疫学
炎症
病理
间充质干细胞
生物信息学
内分泌学
程序性细胞死亡
肾小管
作者
Chunting Guo,Xiangling Li,Zhaoyang Fan,Jiaxuan Zhang,Mingjie Chen
标识
DOI:10.1080/07853890.2025.2561232
摘要
BACKGROUND: Chronic kidney disease (CKD) is the end stage of progressive renal disorders, and effective disease modifying treatments remain elusive. Diabetic kidney disease (DKD) is its leading cause, yet mechanisms and therapies still hold large knowledge gaps. Studies have demonstrated that tubules and interstitium constitute 90 % of renal parenchyma and drive DKD progression; high-glucose milieu induces renal tubular epithelial cell (RTEC) senescence, a process central to DKD onset and worsening. METHODS: Using PubMed as the primary data source, this review first screened literature on 'DKD pathogenesis', revealing that the pivotal role of 'complement activation-induced cellular senescence' remains insufficiently characterized. A second, focused search was then conducted on 'complement system activation', from which studies explicitly linking complement activation to cellular senescence were distilled. The final corpus is organized around three core dimensions: latest discoveries, current research status, and mechanism-guided therapeutic strategies. RESULTS: Cellular senescence, defined as the irreversible growth arrest of cells in response to damaging stimuli, involves various mechanisms such as DNA methylation, oxidative stress, DNA damage response (DDR), mitochondrial dysfunction, and the continuous production of senescence-associated secretory phenotype (SASP) factors. Complement activation induces cellular senescence through the aforementioned processes, thereby promoting and exacerbating both the onset and progression of DKD. CONCLUSION: In the high-glucose milieu, complement activation drives massive C5a release, which accelerates DKD progression by inducing renal tubular cell senescence. C5a-receptor antagonists have already demonstrated potent renoprotective effects, positioning C5a as a central target for future DKD drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI